Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun;82(11):1851–1859. doi: 10.1054/bjoc.2000.1155

Deficient activation of CD95 (APO-1/ Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma

U Ramp 1, M Dejosez 1, C Mahotka 1, B Czarnotta 1, T Kalinski 1, M Wenzel 1, I Lorenz 2, M Müller 3, P Krammer 4, H E Gabbert 1, C D Gerharz 1
PMCID: PMC2363218  PMID: 10839301

Abstract

The pronounced resistance of human renal cell carcinoma (RCC) to anticancer-induced apoptosis has primarily been related to the expression of P-glycoprotein and effective drug detoxification mechanisms. Because the CD95 system has recently been identified as a key mediator of anticancer drug-induced apoptosis, we analysed the contribution of the CD95 system to chemotherapy-induced apoptosis in four newly established RCC cell lines. Here, we demonstrate that all RCC cell lines expressed CD95-receptor and -ligand. Exposure to agonistic anti-CD95 antibodies resulted in induction of apoptosis and significant (P< 0.05) reduction of cell number in three out of four cell lines, indicating that the essential components for CD95-mediated apoptosis were present and functionally intact in the majority of these RCC cell lines. Moreover, treatment of cultures with bleomycin or topotecan, a novel topoisomerase I inhibitor with little substrate affinity for P-glycoprotein, led to induction of apoptosis and significant (P< 0.05) dose-dependent reduction of cell number in all RCC cell lines. Both anticancer drugs also induced upregulation of CD95 ligand expression in all cell lines. Additionally, augmentation of CD95 receptor expression was found in three RCC cell lines, including one p53-mutated cell line, whereas another p53-mutated cell line showed no or only a weak CD95 receptor upregulation after exposure to topotecan or bleomycin, respectively. Despite this upregulation of CD95 receptor and ligand, antagonistic antibodies directed against CD95 receptors or ligands could not inhibit induction of apoptosis by topotecan and bleomycin in any cell line. Thus, although a functionally intact CD95 signalling cascade is present in most RCC cell lines, the anticancer drugs topotecan and bleomycin that induce upregulation of CD95 receptor and ligand fail to effectively activate CD95-mediated apoptosis. This deficient activation of CD95-mediated apoptosis might be an important additional factor for the multidrug resistance phenotype of human RCCs. © 2000 Cancer Research Campaign

Keywords: CD95 (APO-1/Fas), apoptosis, anticancer drugs, multidrug resistance, renal cell carcinoma

Full Text

The Full Text of this article is available as a PDF (191.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldini N. Multidrug resistance--a multiplex phenomenon. Nat Med. 1997 Apr;3(4):378–380. doi: 10.1038/nm0497-378. [DOI] [PubMed] [Google Scholar]
  2. Caignard A., Guillard M., Cai Z., Asselin-Paturel C., Carayol G., Chouaib S. The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas-L cytotoxic pathway. Tissue Antigens. 1996 Oct;48(4 Pt 1):295–300. doi: 10.1111/j.1399-0039.1996.tb02648.x. [DOI] [PubMed] [Google Scholar]
  3. Cascino I., Fiucci G., Papoff G., Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995 Mar 15;154(6):2706–2713. [PubMed] [Google Scholar]
  4. Friesen C., Fulda S., Debatin K. M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997 Nov;11(11):1833–1841. doi: 10.1038/sj.leu.2400827. [DOI] [PubMed] [Google Scholar]
  5. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996 May;2(5):574–577. doi: 10.1038/nm0596-574. [DOI] [PubMed] [Google Scholar]
  6. Fulda S., Los M., Friesen C., Debatin K. M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer. 1998 Mar 30;76(1):105–114. doi: 10.1002/(sici)1097-0215(19980330)76:1<105::aid-ijc17>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  7. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997 Sep 1;57(17):3823–3829. [PubMed] [Google Scholar]
  8. Gerharz C. D., Hildebrandt B., Moll R., Ramp U., Sarbia M., Störkel S., Koldovsky P., Gabbert H. E. Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines. Br J Cancer. 1996 Nov;74(10):1605–1614. doi: 10.1038/bjc.1996.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gerharz C. D., Moll R., Störkel S., Ramp U., Hildebrandt B., Molsberger G., Koldovsky P., Gabbert H. E. Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma. Am J Pathol. 1995 Apr;146(4):953–962. [PMC free article] [PubMed] [Google Scholar]
  10. Gerharz C. D., Moll R., Störkel S., Ramp U., Thoenes W., Gabbert H. E. Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. Am J Pathol. 1993 Mar;142(3):851–859. [PMC free article] [PubMed] [Google Scholar]
  11. Gerharz C. D., Ramp U., Olert J., Moll R., Störkel S., Marx N., Gabbert H. E. Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type. Virchows Arch. 1994;424(4):403–409. doi: 10.1007/BF00190563. [DOI] [PubMed] [Google Scholar]
  12. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  13. Hendricks C. B., Rowinsky E. K., Grochow L. B., Donehower R. C., Kaufmann S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992 Apr 15;52(8):2268–2278. [PubMed] [Google Scholar]
  14. Herben V. M., ten Bokkel Huinink W. W., Beijnen J. H. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996 Aug;31(2):85–102. doi: 10.2165/00003088-199631020-00001. [DOI] [PubMed] [Google Scholar]
  15. Hetts S. W. To die or not to die: an overview of apoptosis and its role in disease. JAMA. 1998 Jan 28;279(4):300–307. doi: 10.1001/jama.279.4.300. [DOI] [PubMed] [Google Scholar]
  16. Hickman J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992 Sep;11(2):121–139. doi: 10.1007/BF00048059. [DOI] [PubMed] [Google Scholar]
  17. Homma Y., Aso Y. Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. Eur Urol. 1994;25(2):164–170. doi: 10.1159/000475273. [DOI] [PubMed] [Google Scholar]
  18. Horie S., Kano M., Higashihara E., Moriyama N., Tanaka E., Hirose A., Kakizoe T., Kawabe K. Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol. 1997 Dec;27(6):384–388. doi: 10.1093/jjco/27.6.384. [DOI] [PubMed] [Google Scholar]
  19. Keane M. M., Ettenberg S. A., Lowrey G. A., Russell E. K., Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 1996 Oct 15;56(20):4791–4798. [PubMed] [Google Scholar]
  20. Kischkel F. C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P. H., Peter M. E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995 Nov 15;14(22):5579–5588. doi: 10.1002/j.1460-2075.1995.tb00245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Krammer P. H. The tumor strikes back: new data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology. Cell Death Differ. 1997 Jul;4(5):362–364. doi: 10.1038/sj.cdd.4400252. [DOI] [PubMed] [Google Scholar]
  22. Mickisch G., Bier H., Bergler W., Bak M., Tschada R., Alken P. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int. 1990;45(3):170–176. doi: 10.1159/000281701. [DOI] [PubMed] [Google Scholar]
  23. Mitsui I., Kumazawa E., Hirota Y., Aonuma M., Sugimori M., Ohsuki S., Uoto K., Ejima A., Terasawa H., Sato K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776–782. doi: 10.1111/j.1349-7006.1995.tb02468.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Miyake H., Hara I., Gohji K., Arakawa S., Kamidono S. p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int J Oncol. 1998 Feb;12(2):469–473. doi: 10.3892/ijo.12.2.469. [DOI] [PubMed] [Google Scholar]
  25. Moll U. M., Schramm L. M. p53--an acrobat in tumorigenesis. Crit Rev Oral Biol Med. 1998;9(1):23–37. doi: 10.1177/10454411980090010101. [DOI] [PubMed] [Google Scholar]
  26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  27. Mulders P., Figlin R., deKernion J. B., Wiltrout R., Linehan M., Parkinson D., deWolf W., Belldegrun A. Renal cell carcinoma: recent progress and future directions. Cancer Res. 1997 Nov 15;57(22):5189–5195. [PubMed] [Google Scholar]
  28. Müller M., Strand S., Hug H., Heinemann E. M., Walczak H., Hofmann W. J., Stremmel W., Krammer P. H., Galle P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997 Feb 1;99(3):403–413. doi: 10.1172/JCI119174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Müller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S. L., Galle P. R., Stremmel W., Oren M. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998 Dec 7;188(11):2033–2045. doi: 10.1084/jem.188.11.2033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nagata S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):281–287. doi: 10.1098/rstb.1994.0107. [DOI] [PubMed] [Google Scholar]
  31. Nakajima H., Yamada N., Takiguchi M. Fas-independent apoptosis of T cells via killer cell inhibitory receptors. Int Immunol. 1998 Jan;10(1):85–90. doi: 10.1093/intimm/10.1.85. [DOI] [PubMed] [Google Scholar]
  32. Natoli G., Ianni A., Costanzo A., De Petrillo G., Ilari I., Chirillo P., Balsano C., Levrero M. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene. 1995 Sep 21;11(6):1157–1164. [PubMed] [Google Scholar]
  33. Nonomura N., Miki T., Yokoyama M., Imazu T., Takada T., Takeuchi S., Kanno N., Nishimura K., Kojima Y., Okuyama A. Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Commun. 1996 Dec 24;229(3):945–951. doi: 10.1006/bbrc.1996.1906. [DOI] [PubMed] [Google Scholar]
  34. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996 Sep 1;184(3):1075–1082. doi: 10.1084/jem.184.3.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Owen-Schaub L. B., Zhang W., Cusack J. C., Angelo L. S., Santee S. M., Fujiwara T., Roth J. A., Deisseroth A. B., Zhang W. W., Kruzel E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995 Jun;15(6):3032–3040. doi: 10.1128/mcb.15.6.3032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Peter M. E., Dhein J., Ehret A., Hellbardt S., Walczak H., Moldenhauer G., Krammer P. H. APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Int Immunol. 1995 Nov;7(11):1873–1877. doi: 10.1093/intimm/7.11.1873. [DOI] [PubMed] [Google Scholar]
  37. Ramp U., Jaquet K., Reinecke P., Nitsch T., Gabbert H. E., Gerharz C. D. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest. 1997 May;76(5):739–749. [PubMed] [Google Scholar]
  38. Reiter R. E., Anglard P., Liu S., Gnarra J. R., Linehan W. M. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res. 1993 Jul 1;53(13):3092–3097. [PubMed] [Google Scholar]
  39. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K. J., Debatin K. M., Krammer P. H., Peter M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998 Mar 16;17(6):1675–1687. doi: 10.1093/emboj/17.6.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Scheithauer W., Clark G. M., Salmon S. E., Dorda W., Shoemaker R. H., Von Hoff D. D. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep. 1986 Dec;70(12):1379–1382. [PubMed] [Google Scholar]
  41. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M. E. Apoptosis signaling by death receptors. Eur J Biochem. 1998 Jun 15;254(3):439–459. doi: 10.1046/j.1432-1327.1998.2540439.x. [DOI] [PubMed] [Google Scholar]
  42. Sorensen M., Sehested M., Jensen P. B. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer. 1995 Aug;72(2):399–404. doi: 10.1038/bjc.1995.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med. 1996 Dec;2(12):1361–1366. doi: 10.1038/nm1296-1361. [DOI] [PubMed] [Google Scholar]
  44. Tomita Y., Kawasaki T., Bilim V., Takeda M., Takahashi K. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer. 1996 Sep 27;68(1):132–135. doi: 10.1002/(SICI)1097-0215(19960927)68:1<132::AID-IJC23>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  45. Waldman T., Kinzler K. W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995 Nov 15;55(22):5187–5190. [PubMed] [Google Scholar]
  46. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES